证券代码：688029 证券简称：南微医学 公告编号：2025-039 南微医学科技股份有限公司 关于召开2025年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） （网址：http://roadshow.sseinfo.com/） 三、参加人员 董事、执行总裁李常青先生，高级副总裁兼财务负责人芮晨为先生，独立 董事解亘先生，副总裁兼董事会秘书龚星亮先生（如有特殊情况，参会人员可 能进行调整）。 投资者可于2025年9月4日(星期四)至9月10日(星期三)16:00前登录上证 路演中心网站首页点击"提问预征集"栏目或将有关问题通过电子邮件的 形式发送至公司投资者关系邮箱nwyx@mtmed.com。公司将在说明会上对投 资者普遍关注的问题进行回答。 一、说明会类型 南微医学科技股份有限公司（以下简称"公司"）已于2025年8月12日在上 海证券交易所网站（www.sse.com.cn）披露《2025年半年度报告》。为便 ...

Group 1 - The company, Nanwei Medical, announced on September 2 that it has repurchased a total of 94,068 shares through the Shanghai Stock Exchange trading system, which represents 0.0501% of its total share capital of 187,847,422 shares [1]

证券代码：688029 证券简称：南微医学 公告编号：2025-038 南微医学科技股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 特此公告。 2025 年 8 月，公司通过上海证券交易所交易系统以集中竞价交易方式已累计 回购股份 94,068 股，占公司总股本 187,847,422 股的比例为 0.0501%,回购成交的 最高价为 93.76 元/股，最低价为 88.92 元/股，支付的资金总额为人民币 8,627,597.39 元（不含印花税、交易佣金等交易费用）。 截至 2025 年 8 月 31 日，公司已累计回购股份 109,797 股，占公司总股本的 比例为 0.0585%，购买的最高价为 93.76 元/股，最低价为 62.01 ...

Summary of Key Points - The company Nanwei Medical (688029.SH) announced a share buyback program, having repurchased a total of 109,797 shares as of August 31, 2025, which represents 0.0585% of its total share capital [1] - The highest price paid for the repurchased shares was 93.76 CNY per share, while the lowest price was 62.01 CNY per share [1] - The total amount spent on the share buyback was 9,604,989.12 CNY, excluding transaction fees such as stamp duty and trading commissions [1]

Investment Rating - The report suggests a positive outlook for the medical device industry, indicating that the adjustment period is nearing its end and a recovery is expected in the second half of 2025 [2][4]. Core Insights - The medical device sector is experiencing a recovery trend, with domestic bidding demand showing signs of restoration in the second half of 2025 after a significant decline due to policy delays [2]. - The medical consumables segment is steadily growing, with a slight increase in gross margin, indicating resilience in demand related to patient treatment needs [2]. - The in-vitro diagnostics sector is under pressure, but there is potential for increased domestic market share for local manufacturers in the long term [2]. - Leading medical device companies are accelerating their overseas market expansion, with many reporting higher growth rates in international markets compared to domestic ones [2]. Summary by Sections Medical Equipment - Revenue for Q2 2025 showed a year-on-year decline of 5.26%, with net profit down 27.93% and gross margin decreasing from 53.07% in Q2 2024 to 49.00% in Q2 2025 [16]. - The industry is expected to reach a turning point as domestic bidding demand recovers [2][18]. Medical Consumables - Q2 2025 revenue increased by 1.33% year-on-year, with net profit down 6.28% and a slight improvement in gross margin from 42.13% to 42.24% [23]. - The segment is characterized by stable growth, with companies focusing more on R&D and innovative products [2]. In-Vitro Diagnostics - Revenue for Q2 2025 decreased by 16.53% year-on-year, with net profit down 37.58% and gross margin declining from 62.43% to 59.66% [29]. - The sector faces short-term demand pressure but may benefit from increased domestic production rates in the long run [2]. Investment Recommendations - The report recommends focusing on three key areas: companies leading in international market product and channel expansion, domestic medical device industry leaders, and high-value consumables firms with strong innovation capabilities [34]. - Specific companies to watch include Nanwei Medical, Mindray Medical, Sanofi, and Xinjiang Technology [34].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [5] Core Views - The pharmaceutical sector is expected to continue its recovery, with a focus on innovative drugs as the main investment theme. The report highlights a gradual improvement in the industry, with Q2 showing a significant reduction in the decline of revenue and profits compared to Q1 [7][21][19] - The report emphasizes the potential for a turnaround in the industry, driven by policy improvements, demand recovery, and the performance of the CRO/CDMO segments [10][16] Summary by Sections Market Performance - In August 2025, the pharmaceutical and biotechnology sector rose by 2.6%, underperforming the Shanghai and Shenzhen 300 index, which increased by 10.3%. The sector ranked 24th among 31 sub-industries [7][15] - The report notes a mixed performance among sub-sectors, with medical devices and services showing gains, while the pharmaceutical commercial sector declined [15] Financial Performance - In the first half of 2025, the cumulative revenue of pharmaceutical companies decreased by 2.6%, with total profits down by 4.0%. However, Q2 showed a narrowing of declines, with revenue down by only 1.1% and total profits down by 2.9% [21][19] - The report indicates that the CRO/CDMO segments performed well, with significant revenue and profit growth, particularly in Q2 [21][19] Investment Opportunities - The report suggests focusing on innovative drugs, which are seen as having strong growth potential and clear industry trends. It recommends several companies across different categories, including biotech firms transitioning to biopharma and large pharmaceutical companies involved in innovative drug development [9][10][11] - The report also highlights the potential for recovery in the CRO/CDMO segments and suggests that companies in these areas are likely to benefit from improving demand and order recovery [10][16] Key Recommendations - The report lists key companies to watch, including WuXi AppTec, WuXi Biologics, and others, indicating a positive outlook for these firms based on their performance and market position [17][18]

Meeting Overview - The shareholders' meeting of Nanwei Medical Technology Co., Ltd. was held on a specified date in Nanjing, with 153 ordinary shareholders present, holding a total of 104,032,451 voting rights, which accounts for 55.6545% of the company's total voting rights [1][2] Voting Results - All non-cumulative voting proposals were approved, with the first proposal receiving 99.9829% approval from ordinary shareholders, while the second proposal received 99.9888% approval [1][2] - The voting results indicate a strong consensus among shareholders, with minimal opposition and abstentions [1] Legal Compliance - The meeting's procedures, including the gathering, attendance, voting methods, and results, were confirmed to comply with the Company Law and relevant regulations, ensuring the legality and validity of the resolutions made [2]

Core Viewpoint - The legal opinion letter confirms the legality of the second extraordinary general meeting of shareholders of Nanwei Medical Technology Co., Ltd., ensuring compliance with relevant laws and regulations [1][2][3]. Group 1: Meeting Procedures - The meeting was convened by the company's board of directors, with a notice issued 15 days prior to the meeting, detailing the time, location, agenda, and voting methods [2][3]. - The meeting utilized a combination of on-site and online voting, with specific time slots allocated for online voting through the Shanghai Stock Exchange trading system [3]. Group 2: Attendance and Voting - A total of 9 shareholders and their proxies attended the on-site meeting, holding 42,320,774 voting shares, which accounts for 22.6405% of the total voting shares [4]. - Additionally, 144 shareholders participated in online voting, holding 61,711,677 voting shares, representing 33.0141% of the total voting shares [4]. - The meeting included company directors, supervisors, senior management, and the appointed lawyers in attendance [4]. Group 3: Proposals and Voting Results - No new proposals were presented during the meeting [5]. - The voting process was conducted through a named voting method, with results announced immediately after counting, confirming the legality and validity of the voting procedures and results [5]. Group 4: Conclusion - The legal opinion concludes that all aspects of the meeting, including convening, attendance, voting methods, and results, comply with the Company Law, relevant regulations, and the company's articles of association, rendering the resolutions made at the meeting legal and valid [5].

证券代码：688029 证券简称：南微医学 公告编号：2025-037 南微医学科技股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 （二） 股东大会召开的地点：南京江北新区药谷大道 199 号公司 9 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 153 | | --- | --- | | 普通股股东人数 | 153 | | 2、出席会议的股东所持有的表决权数量 | 104,032,451 | | 普通股股东所持有表决权数量 | 104,032,451 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 55.6545 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 55.6545 | 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 8 月 27 日 ...

江苏新高的律师事务所 关于 南微医学科技股份有限公司 2025 年第二次临时股东大会的 见证法律意见书 地址：南京市秦淮区龙蟠中路 419 号人保（南京）金融大厦 A 座 9、10 楼 电话：（025）84715285 传真：（025）84703306 邮编：210001 致：南微医学科技股份有限公司 江苏新高的律师事务所（以下简称"本所"）接受南微医学科技股份有限公 司（以下简称"公司"）委托，指派张玫、张一泓律师（以下简称"本所律师"） 出席公司 2025 年第二次临时股东大会（以下简称"本次股东大会"），就本次 股东大会的合法性进行见证并出具法律意见书。 本法律意见书依据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规 则》（以下简称"《规则》"）等相关法律、法规和规范性文件以及《南微医学 科技股份有限公司章程》（以下简称"《公司章程》"）的规定而出具。 公司已向本所承诺：公司所提供的文件和所作陈述及说明是完整、真实、有 效的，有关原件及其签字和印章是真实的，且一切足以影响本法律意见书的事实 和文件均已向本所披露，无任何隐瞒、疏 ...